Sigma-Aldrich Corporation (SIAL - Analyst Report) announced that its Cerilliant brand has launched four new Certified Spiking Solutions of the corticosteroids pregnenolone, 17alpha-hydroxypregnenolone, cortisone, and 11-deoxycorticosterone at concentrations of 100 ug/mL in methanol. The shares of Sigma-Aldrich rose as much as around 1.4% during the trading hours following the news announcement.
The new solutions have all the requisites necessary for applications ranging from diagnostic testing and clinical chemistry to endocrinology and neonatal screening. The stable quantitative solution format of Cerilliant's Spiking Solutions provides the laboratory benefits such as increased efficiency of labor and convenience of use.
The LC-MS/MS is well established for neonatal screening and Pain management clinics are increasingly using LC-MS/MS methods to quantify hormones such as pregnenolone, 17alpha-hydroxypregnenolone, and cortisone in patient serum. These hormones serve as biomarkers of pain and indicators of abnormal hormone production.
Cerilliant’s catalog includes a wide range of analytical standards for forensic, clinical, pharmaceutical, nutraceutical, environmental testing and research with an emphasis on Certified Solutions Standards and Certified Spiking Solutions. Cerilliant provides solution-based reference standards for use in a wide range of analytical applications ranging from clinical and diagnostic testing, toxicology and therapeutic drug monitoring to emerging applications in endocrinology, clinical chemistry and pain management.
Sigma-Aldrich , a life science and high technology company, develops, manufactures, purchases, and distributes various chemicals, biochemicals, and equipment worldwide.
Sigma-Aldrich carries a Zacks Rank #3 (Hold).
Other companies in the specialty chemicals space worth considering are Globe Specialty Metals, Inc. (GSM - Snapshot Report), International Flavors & Fragrances Inc. (IFF - Analyst Report) and Rockwood Holdings Inc. (ROC - Snapshot Report), each carrying a Zacks Rank #2 (Buy).
Read the Full Research Report on SIALRead the Full Research Report on IFFRead the Full Research Report on ROCRead the Full Research Report on GSMZacks Investment Research